We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Association of G9a Protein and the Outcome of Patients With Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01505751
Recruitment Status : Completed
First Posted : January 9, 2012
Last Update Posted : September 7, 2016
Sponsor:
Information provided by (Responsible Party):
Sheng-Mou Hsiao, Far Eastern Memorial Hospital

Brief Summary:
G9a protein was approved to be highly associated with recurrence of breast cancer, gastric cancer, hepatocellular cancer, prostate cancer and lung cancer. Therefore, the aim of this study was to clarify the association and G9a protein and cervical cancer by analyzing the immunohistochemical staining of G9a protein to the histopathologic specimen of cervical cancer and clinical data.

Condition or disease
Cervical Cancer

Study Type : Observational
Actual Enrollment : 69 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Study Start Date : February 2012
Primary Completion Date : February 2015
Study Completion Date : February 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer
U.S. FDA Resources

Group/Cohort
cervical cancer



Primary Outcome Measures :
  1. determine whether G9a protein is a risk factor of overall survival of patients with cervical cancer [ Time Frame: From the date of primary treatment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 100 months ]

Secondary Outcome Measures :
  1. determine whether G9a protein is a risk factor of progression-free survival of patients with cervical cancer [ Time Frame: From the date of primary treatment until the date of first documented progression or last follow-up, whichever came first, assessed up to 100 months ]

Biospecimen Retention:   Samples With DNA
Residual pathology block after pathological exam


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with cervical cancer, and underwent primary treatment (surgery, radiotherapy or chemotherapy) in Far Eastern Memorial Hospital
Criteria

Inclusion Criteria:

  • cases with cervical cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01505751


Locations
Taiwan
Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
Banqiao, New Taipei, Taiwan, 22050
Sponsors and Collaborators
Far Eastern Memorial Hospital

Responsible Party: Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier: NCT01505751     History of Changes
Other Study ID Numbers: 100078-E
First Posted: January 9, 2012    Key Record Dates
Last Update Posted: September 7, 2016
Last Verified: July 2015

Keywords provided by Sheng-Mou Hsiao, Far Eastern Memorial Hospital:
Outcome of cervical cancer

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female